{"nctId":"NCT00130793","briefTitle":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)","startDateStruct":{"date":"2005-08"},"conditions":["Herpes Zoster"],"count":368,"armGroups":[{"label":"zoster vaccine live (Oka/Merck) refrigerated formulation","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation"]},{"label":"zoster vaccine live (Oka/Merck) frozen formulation","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: zoster vaccine live (Oka/Merck) frozen formulation"]}],"interventions":[{"name":"Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation","otherNames":[]},{"name":"Comparator: zoster vaccine live (Oka/Merck) frozen formulation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Individuals who are at least 50 years of age or older with a history of varicella (chicken pox)\n\nExclusion Criteria:\n\n* Prior history of herpes zoster (shingles)\n* Prior receipt of varicella or zoster vaccine\n* Immunosuppressed","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination","description":"The GMT of the VZV-specific antibody responses as measured by gpELISA (glycoprotein enzyme-linked immunosorbent assay) at 4 weeks postvaccination in subjects who received ZOSTAVAX™ with PGSU and in subjects who received ZOSTAVAX™ with PGS.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"717.5","spread":null},{"groupId":"OG001","value":"844.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Vaccine-Related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination","description":"Vaccine-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) serious adverse experiences are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"183","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination","description":"GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":180},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Injection site pruritus"]}}}